Last reviewed · How we verify
NCT05067920
Correlation Between Cycle Threshold (Ct) Values in COVID-19, Health Status and Laboratory Biomarkers in the Population of Medellin- Colombia Evaluated in a Specialized Laboratory.
trial testing Levels of SARS-COV-2 antibodies in Covid19 in 120 participants. Status unknown.
30 January 2022
Quick facts
| Lead sponsor | Universidad de Antioquia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 27 September 2021 |
| Primary completion | 30 January 2022 |
| Estimated completion | 31 January 2022 |
| Sites | 1 location across Colombia |
Drugs / interventions tested
- Levels of SARS-COV-2 antibodies
- rRT-PCR SARS-Cov-2
- Hematological and immunological biomarkers
- Mitochondrial DNA
- SARS-CoV-2 Viral Culturing
- Sequencing COVID-19
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Universidad de Antioquia — full company profile →
Who can join
Adults 18 to 99, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the correlation between the symptomaticity, Ct value, laboratory biomarkers associated to COVID-19 and the disease progression in hospitalized patients and outpatients with SARS-CoV2 infection diagnosed by RT-PCR assay for nasopharyngeal swab specimens in a specialized laboratory at Medellin,Colombia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05067920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Universidad de Antioquia trials
Trials by the same sponsor.
- NCT06774274 — Analgesic Efficacy of Intravenous Ketamine as a Continuous Infusion vs PCA in the Management of Acute Postoperative Pain · Phase 4 · recruiting
- NCT06693869 — The Risk of Surgical Cancellation in Adult Patients Assessed by Telephone Versus In-person for Scheduled Non-cardiac Ele · not yet recruiting
- NCT07179432 — Effectiveness of Facial Mask NIV in Adults Under General Anesthesia: Two-Hand C-E vs V-E Techniques · NA · recruiting
- NCT06742827 — Educational Intervention and Adherence · NA · active not recruiting
- NCT06911736 — Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05067920 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad de Antioquia
- Last refreshed: 28 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05067920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing